An experienced Biopharma Executive with over 25+ years’ experience Greg has developed and successfully executed financially responsible strategies in executive level roles ranging from CEO, COO, Sales Management, Market Access, Marketing, and Business Development.
Greg has consistently demonstrated the ability to build and effectively manage departments across a myriad of therapeutic classes. Most recently at Zimmer Biomet/Biologics Division as VP, Marketing, Greg managed and developed successful strategies for the companies first prescription injectable product, Gel-One. While at Savient Greg lead the build out of the company’s biologics arm taking responsibility for Operations, Sales and Managed Care in support of Euflexxa the company’s first biologic launch.
Recruited by Andrx Laboratories, he was part of the senior management team that established Andrx in the branded marketplace and took responsibility for managing the team that successfully launched Altoprev and Fortamet the company’s first branded products. Beginning his career at Forest Laboratories Greg quickly elevated himself and took responsibility for the Managed Care department in support of the company’s first blockbuster Tiazac.
Greg is an industry consultant for Gerson Lehrman Group, Third Bridge and an associate member of the Academy of Managed Care Pharmacy.
Greg graduated from Illinois State University with a degree in Political Science.
Rajesh brings extensive experience in entrepreneurial biotechnology, midsize and large pharmaceutical companies with proven institutional stewardship, developing strategic alliances with global corporate, academic, regulatory, and defense entities. Rajesh’s depth in scientific, engineering, clinical, medical and regulatory management of large and complex clinical development programs with academic clinical centers, alliance partners, HHS and DoD/MoD agencies has attracted more than $100MM in external clinical development funding. He has more than 60 peer reviewed publications, global patents and presentations in drug design, medical devices and clinical research.
Rajesh began his pharmaceutical career at Bristol Myers-Squibb leveraging novel approaches in drug design and development in oncology and immunology such as chemokine receptor and proinflammatory cytokine antagonists and PLA2 inhibitors. Subsequently he led R&D programs designing novel agents targeting glioblastomas funded through NIH grants at start-up biotechnology companies. During his recent tenure at Pfizer, Rajesh led advances in the treatment of acute immune system diseases and epilepsies.
Prior to joining Castle Creek, Rajesh led clinical affairs and development, medical and regulatory affairs at Motif Biosciences, Acorda therapeutics and Pfizer with a primary focus on global Orphan disease trials. His trial design and execution experience cover conventional, complex innovative designs, interventional, non-interventional, nation-wide community consent and human factors engineering trials. The breadth of his drug and drug/device clinical development expertise spans from Phase I through Phase 3, post-approval and registry trials. Rajesh has led global medical advisory boards in immunology, CNS, infectious diseases, hepatology and nephrology for strategic oversight of medical affairs and clinical development resulting in numerous NDA submissions and approvals.
Rajesh’s R&D career began after completing his postdoctoral tenure at Yale University. As an Easton, Pennsylvania native, he completed bachelor’s degree in Biochemistry from Lehigh University and his PhD from Carnegie-Mellon University.
Ron brings more than 30 years’ experience in the pharmaceutical industry. Ron is an accomplished operations executive with a broad experience base in drug development, clinical and commercial manufacture of biologics. Ron also has an in depth experience in aseptic processing and manufacturing parenterals.
Ron’s career started at Johnson & Johnson where he held several leadership roles and ultimately was responsible for a worldwide launch of a new blood type and screening diagnostic. Ultimately Ron became responsible for Johnson & Johnson’s Blood Bank Operations, which included their parenteral vaccine division.
Due to Ron’s broad based background he has been key in transitioning small to mid-sized biopharmaceuticals from R & D to commercial manufacturing to accomplish successful launch. In addition to Johnson & Johnson, Ron also held several leadership roles at Liposome, Elan, Enzon, NPS and Shire Pharmaceuticals. Ron has worked on a wide range of products that encompass unique processes such as liposomal encapsulation, PEGylation, lypohilization, plasma fractionation, etc. His responsibilities have not only encompassed domestic responsibilities, but he has been responsible for CMO oversight and worked international throughout Europe and Asia.
In virtually every role, Ron has been responsible to ensure compliance with respect to cGMPs and has a vast amount of experience working with regulatory agencies such as the FDA and EMEA. He has been key in reviewing and writing INDs, NDAs, SNDAs, MBRs, SOPs, RFPs, SOWs and has been instrumental to ensure readiness for PAIs.
Ron also has an extensive background in Project Management, which has encompassed technology transfer, scale-up and build-out of sterile manufacturing facilities.
Ron holds a BS degree in biology from Rutgers University and an M.B.A. in Business from Fairleigh Dickinson University.
Michael Derby is the Vice Chairman of Castle Creek Pharmaceuticals, which he has built from a complete startup to one of the fastest growing specialty pharmaceutical companies in the industry. Castle Creek has rapidly assembled a robust portfolio of products backed by strong science and focused on meeting patient needs in the treatment of rare and debilitating dermatologic conditions.
Mr. Derby is a successful entrepreneur, operating executive and investor, with 20 years of experience in the pharmaceutical industry and broader life sciences sector. He has founded or co-founded four specialty pharmaceutical companies, and has a passion for developing and commercializing innovative drugs for patients with rare diseases and other serious medical conditions.
Mr. Derby holds advanced degrees in business and science, with an M.B.A., with distinction, from New York University’s Stern School of Business, an M.S. in Neuroscience from the University of Rochester, and a B.S., with honors, from Johns Hopkins University, where he was a Beneficial Hodson merit scholar and member of the Tau Beta Pi engineering honor society.